Akoya Biosciences, Inc., a Menlo Park, Calif.-based spatial biology company, closed a $50m financing.
The round was led by Piper Jaffray Merchant Banking, a division of Piper Jaffray, with participation from Telegraph Hill Partners and new strategic partners Agilent Technologies and Innovatus Capital Partners, LLC. In conjunction with the funding, Thomas Schnettler, managing director at Piper Jaffray, joined Akoya’s Board of Directors.
The company intends to use the funds for expansion of commercial and operational resources as well as continued product development of its CODEX? and Phenoptics? platforms for spatial biology for research and clinical markets.
Led by Brian McKelligon, Chief Executive Officer, Akoya offers comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
The company has two platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders:
– the CODEX? system, a benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery, and
– the Phenoptics? platform, a multiplexed immunofluorescence solution with the high throughput necessary for translational research and clinical trials.